Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Lindholm, Daniel; Lindbäck, Johan; Armstrong, Paul W.; Budaj, Andrzej; Cannon, Christopher P.; Granger, Christopher B.; Hagström, Emil; Held, Claes; Köenig, Wolfgang; Östlund, Ollie; Stewart, Ralph; Soffer, Joseph; White, Harvey D.; Winter, Robbert J. de; Steg, Philippe Gabríel; Siegbahn, Agneta; Kleber, Marcus E.; Dressel, Alexander; Grammer, Tanja B.; März, Winfried; Wallentin, Lars

doi:10.1016/j.jacc.2017.06.030

Cited by 112 publications

(77 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score is based on a database from 1999 to 2000. Recently, the ABC‐CHD tool showed good ability to predict cardiovascular mortality for patients with SCAD. However, the study that determined this result enrolled relatively high‐risk patients and did not target the PCI population.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention

Zhao

Xian

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives To assess the predictive value of the Global Registry of Acute Coronary Events (GRACE) discharge score for patients with stable coronary artery disease (SCAD) after percutaneous coronary intervention (PCI). Background The GRACE score is widely used for predicting the mortality of acute coronary syndrome patients. However, the predictive value of SCAD has not been sufficiently studied. Methods We studied 4,293 consecutive patients with SCAD who underwent PCI between January 2013 and December 2013. The primary endpoint was all‐cause mortality and the secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE). Results Among 3,915 patients with SCAD following PCI, there were 38 deaths and 394 MACCE during 2 years of follow‐up. The GRACE discharge score was significantly higher for patients who died than for those who survived (86.97 ± 23.27 vs. 71.07 ± 19.84; p < .001). Risk stratification of the GRACE score indicated that the mortality risk of the intermediate‐risk and high‐risk groups were 3.23‐fold (hazard ratio [HR], 3.23; range, 1.59–6.55; p = .001) and 15.31‐fold higher (HR, 15.31; range, 4.43–51.62; p < .001), respectively, than that of the low‐risk group. The MACCE risk for the intermediate‐risk and high‐risk groups were 1.28‐fold (HR, 1.28; range, 1.02–1.62; p = .037) and 2.42‐fold higher (HR, 2.42; range, 1.20–4.88; p = .014), respectively. The GRACE discharge score had prognostic value for mortality (area under the receiver operating characteristic curve, 0.692; p < .001). Conclusions The GRACE discharge score is valuable for the risk stratification of death and MACCE, as well as for the prognosis to mortality for SCAD patients who have undergone PCI.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention

Zhao

Xian

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Some models have already been developed and suggest that predictors of risk may be quite different from primary prevention. 13,14 A second interesting development is to adopt a lifetime perspective on CVD risk assessment. Although this was already touched on in the 2016 ESC guideline, and is also part of the 2019 US guideline, 7 there is no consensus as to which level of lifetime risk and at which particular age this risk is calculated should trigger treatment recommendations.…”

Section: Cardiovascular Riskmentioning

confidence: 99%

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology

Piepoli

Abreu

Albus

et al. 2019

Eur J Prev Cardiolog

180

View full text Add to dashboard Cite

European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regularly updated, most recently in 2016, by the Sixth European Joint Task Force. Given the amount of new information that has become available since then, components from the task force and experts from the European Association of Preventive Cardiology of the European Society of Cardiology were invited to provide a summary and critical review of the most important new studies and evidence since the latest guidelines were published. The structure of the document follows that of the previous document and has six parts: Introduction (epidemiology and cost effectiveness); Cardiovascular risk; How to intervene at the population level; How to intervene at the individual level; Disease-specific interventions; and Settings: where to intervene? In fact, in keeping with the guidelines, greater emphasis has been put on a population-based approach and on disease-specific interventions, avoiding re-interpretation of information already and previously considered. Finally, the presence of several gaps in the knowledge is highlighted.

show abstract

“…Contrary to venous thromboembolism (VTE), where the association of D‐dimer levels with VTE‐risk is strong enough to use it in clinical risk prediction, thus far, the associations of coagulation biomarkers with arterial thrombosis have not added significantly to risk prediction of cardiovascular events. Recently, a biomarker‐based prediction model in patients with coronary heart disease (CHD) was published; the “ABC‐CHD” model (Age, Biomarkers, Clinical variables) . However, only cardiac biomarkers, like N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), high‐sensitivity troponin T (hs‐TnT) and LDL‐cholesterol have been incorporated in this prediction model.…”

Section: Biomarkers In Cardiovascular Diseasementioning

confidence: 99%

“…Recently, a biomarker-based prediction model in patients with coronary heart disease (CHD) was published; the "ABC-CHD" model (Age, Biomarkers, Clinical variables). 33 Future studies using a combination of these different groups of biomarkers may increase the accuracy of risk prediction, and should explore their role in personalizing antithrombotic strategies in high-risk cardiovascular disease patients. adverse limb events (MALE) compared to aspirin alone.…”

Section: Biomarkers In Cardiovascular Diseasementioning

confidence: 99%

The coagulation system in atherothrombosis: Implications for new therapeutic strategies

Olie

Meijden

Cate

2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Essentials A State of the Art lecture “Clotting factors and atherothrombosis” was presented at the ISTH congress 2017.Coagulation proteins are not only involved in hemostasis, they also play a role in atherogenesis.Inhibition of coagulation proteins could potentially protect the vessel wall against progression of atherosclerosis.Combining antiplatelet and anticoagulant therapy has been demonstrated to improve cardiovascular outcomes in patients with stable atherosclerotic disease. Clinical manifestations of atherosclerotic disease include coronary artery disease (CAD), peripheral artery disease (PAD), and stroke. Although the role of platelets is well established, evidence is now accumulating on the contribution of coagulation proteins to the processes of atherosclerosis and atherothrombosis. Coagulation proteins not only play a role in fibrin formation and platelet activation, but also mediate various biological and pathophysiologic processes through activation of protease‐activated‐receptors (PARs). Thus far, secondary prevention in patients with CAD/PAD has been the domain of antiplatelet therapy, however, residual atherothrombotic risks remain substantial. Therefore, combining antiplatelet and anticoagulant therapy has gained more attention. Recently, net clinical benefit of combining aspirin with low‐dose rivaroxaban in patients with stable atherosclerotic disease has been demonstrated. In this review, based on the State of the Art lecture “Clotting factors and atherothrombosis” presented at the ISTH Congress 2017, we highlight the role of coagulation proteins in the pathophysiology of atherothrombosis, and specifically focus on therapeutic strategies to decrease atherothrombotic events by optimization of vascular protection.

show abstract

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Cited by 112 publications

References 43 publications

Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention

Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology

The coagulation system in atherothrombosis: Implications for new therapeutic strategies

Contact Info

Product

Resources

About